EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Review on Chronotherapeutic Pulsatile Drug Delivery Systems in Diabetes Mellitus

Saket Singh Rajput, Derhu Jangde, Prince Nikhil Rathor, Suman Shrivastava, Swarnali Das Paul, Rashmi Madhariya

Journal of Pharma Insights and Research · 05.06.2026 · 4 (3) · 341-358

DOI: 10.69613/fn3dtb90 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharma Insights and Research, online erschienen am 05.06.2026. Verfasst von Saket Singh Rajput und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus is a global metabolic crisis characterized by chronic hyperglycemia, where progressive pancreatic -cell dysfunction and peripheral insulin resistance lead to systemic microvascular and macrovascular complications. Although diverse classes of oral and injectable antidiabetic agents exist, conventional static dosing regimens frequently fail to achieve tight glycemic control due to their inability to synchronize with the highly dynamic circadian fluctuations of metabolic physiology. Endogenous insulin secretion, hepatic gluconeogenesis, peripheral glucose uptake, and counter-regulatory hormone actions are tightly governed by the suprachiasmatic nucleus and autonomous peripheral molecular clocks. These circadian oscillations generate predictable temporal patterns of hyperglycemia, such as the early morning dawn phenomenon, nocturnal glycemic instability, and meal-associated postprandial glucose surges. Chronotherapy via pulsatile drug delivery systems offers a sophisticated therapeutic approach by releasing active pharmaceutical ingredients after predetermined lag phases or in direct response to physiological biomarkers. Integrating these systems with smart, glucose-responsive biomaterials, polymeric nanoformulations, and microneedle platforms allows for the biomimetic restoration of physiological insulin profiles and timed delivery of oral secretagogues. Despite technical hurdles regarding batch-to-batch reproducibility, long-term biocompatibility, and complex regulatory approval rules for combination drug-device systems, these responsive technologies represent a critical step toward automated, personalized metabolic management. Aligning therapeutic delivery with the patient's endogenous circadian biology provides a viable pathway to optimize pharmacodynamic outcomes, mitigate nocturnal hypoglycemic crises, and limit cumulative organ damage

Zitieren

APA

Rajput, S. S., Jangde, D., Rathor, P. N., Shrivastava, S., Paul, S. D., & Madhariya, R. (2026). A Review on Chronotherapeutic Pulsatile Drug Delivery Systems in Diabetes Mellitus. Journal of Pharma Insights and Research, 4(3), 341-358. https://doi.org/10.69613/fn3dtb90

Vancouver

Rajput SS, Jangde D, Rathor PN, Shrivastava S, Paul SD, Madhariya R. A Review on Chronotherapeutic Pulsatile Drug Delivery Systems in Diabetes Mellitus. Journal of Pharma Insights and Research. 2026;4(3):341-358. doi:10.69613/fn3dtb90

BibTeX
@article{Rajput2026,
  author = {Rajput, Saket Singh and Jangde, Derhu and Rathor, Prince Nikhil and Shrivastava, Suman and Paul, Swarnali Das and Madhariya, Rashmi},
  title = {A Review on Chronotherapeutic Pulsatile Drug Delivery Systems in Diabetes Mellitus},
  journal = {Journal of Pharma Insights and Research},
  year = {2026},
  volume = {4},
  number = {3},
  pages = {341--358},
  doi = {10.69613/fn3dtb90}
}
Kostenlos starten →